ATX-MS-1467 / Worg Pharma - LARVOL DELTA

ATX-MS-1467 in multiple sclerosis (clinicaltrials.gov) - P2, N=20; Sponsor: Merck KGaA; Not yet recruiting -> Recruiting.

Enrollment open • Multiple Sclerosis

Preclinical efficacy and phase I clinical testing of ATX-MS1467, an antigen-specific immunotherapy for multiple sclerosis (AAN 2014) - Presentation time: Monday, April 28, 2014 3:00 PM; Abstract #P1.189; P1, N=43; Sponsor: Apitope; NCT01097668; "Treatment of double transgenic mice with ATX-MS-1467 resulted in >90% prevention of EAE and suppression of inflammatory cytokine secretion. ATX-MS-1467 was more effective than glatiramer acetate when given at a 70x lower cumulative dose....Patients treated subcutaneously had low MRI activity at week 0 that remained low throughout the trial precluding measuring an effect. There were no unexpected safety signals in any patients treated with ATX-MS-1467."

P1 data • Preclinical • Multiple Sclerosis

Apitope announces positive results from clinical trial of ATX-MS-1467 in relapsing multiple sclerosis (Businesswire) - P1, N=43; NCT01097668; Sponsor: Apitope Technology; "Apitope...announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group. These encouraging results will now need confirmation in appropriate Phase II trials."

Anticipated new P2 trial • P1 data • Multiple Sclerosis

Merck Serono: Q2 2015 Results (Merck Serono) - Anticipated data from P2 trial (NCT01973491) for relapsing multiple sclerosis in 2016

Anticipated P2 data • Multiple Sclerosis

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis -

P1,N=40

Multiple Sclerosis

ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - P2; N=17; Active, not recruiting; Sponsor: Merck KGaA; Recruiting -> Active, not recruiting

Enrollment closed • Biosimilar • Multiple Sclerosis

A future for antigenspecific immunotherapy for multiple sclerosis (ECTRIMS 2019) - "Peptides are designed as antigen processing independent epitopes (Apitopes) that mimic naturally processed antigens. Safety results were unremarkable in both studies. Based on these results we conclude that relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post-treatment."

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. (PubMed, Neurology) - "Relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted."

Journal

Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis. (PubMed, CNS Drugs) - "We review the experimental approaches of tolerance-inducing vaccination in relapsing and progressive forms of MS that have reached the clinical development phase, including vaccination with autologous T cells, autologous tolerogenic dendritic cells, T cell receptor peptide vaccination, altered peptide ligand, ATX-MS-1467, cluster of differentiation (CD)-206-targeted liposomal myelin basic protein peptides and DNA vaccination. Failures, successes and future directions are discussed."

Journal